← Back to headlines
Regeneron Stock Performance After FDA Approval of Hearing Gene Therapy
The article discusses whether Regeneron is a good investment following the FDA's approval of its gene therapy designed to restore hearing.
2 May, 15:20 — 2 May, 15:20
Sources
Showing 1 of 1 sources
